Global Ifosfamide for Injection Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032
1 Market Overview
- 1.1 Product Overview and Scope
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Market Analysis by Type
- 1.3.1 Overview: Global Ifosfamide for Injection Consumption Value by Type: 2021 Versus 2025 Versus 2032
- 1.3.2 0.5 g
- 1.3.3 1.0 g
- 1.3.4 2.0 g
- 1.3.5 3.0 g
- 1.3.6 Other Strengths
- 1.4 Market Analysis by Dosage Form
- 1.4.1 Overview: Global Ifosfamide for Injection Consumption Value by Dosage Form: 2021 Versus 2025 Versus 2032
- 1.4.2 Powder for Injection
- 1.4.3 Ready-to-Use Solution Injection
- 1.4.4 Other Dosage Forms
- 1.5 Market Analysis by Pack Configuration
- 1.5.1 Overview: Global Ifosfamide for Injection Consumption Value by Pack Configuration: 2021 Versus 2025 Versus 2032
- 1.5.2 Single-Vial Pack
- 1.5.3 Multi-Vial Pack
- 1.5.4 Other Pack Configurations
- 1.6 Market Analysis by Application
- 1.6.1 Overview: Global Ifosfamide for Injection Consumption Value by Application: 2021 Versus 2025 Versus 2032
- 1.6.2 Testicular Cancer
- 1.6.3 Soft Tissue Sarcoma
- 1.6.4 Bone Sarcoma
- 1.6.5 Lymphoma
- 1.6.6 Ovarian Cancer
- 1.6.7 Other Malignancies
- 1.7 Global Ifosfamide for Injection Market Size & Forecast
- 1.7.1 Global Ifosfamide for Injection Consumption Value (2021 & 2025 & 2032)
- 1.7.2 Global Ifosfamide for Injection Sales Quantity (2021-2032)
- 1.7.3 Global Ifosfamide for Injection Average Price (2021-2032)
2 Manufacturers Profiles
- 2.1 Baxter
- 2.1.1 Baxter Details
- 2.1.2 Baxter Major Business
- 2.1.3 Baxter Ifosfamide for Injection Product and Services
- 2.1.4 Baxter Ifosfamide for Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.1.5 Baxter Recent Developments/Updates
- 2.2 Fresenius Kabi
- 2.2.1 Fresenius Kabi Details
- 2.2.2 Fresenius Kabi Major Business
- 2.2.3 Fresenius Kabi Ifosfamide for Injection Product and Services
- 2.2.4 Fresenius Kabi Ifosfamide for Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.2.5 Fresenius Kabi Recent Developments/Updates
- 2.3 Hikma
- 2.3.1 Hikma Details
- 2.3.2 Hikma Major Business
- 2.3.3 Hikma Ifosfamide for Injection Product and Services
- 2.3.4 Hikma Ifosfamide for Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.3.5 Hikma Recent Developments/Updates
- 2.4 Shionogi
- 2.4.1 Shionogi Details
- 2.4.2 Shionogi Major Business
- 2.4.3 Shionogi Ifosfamide for Injection Product and Services
- 2.4.4 Shionogi Ifosfamide for Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.4.5 Shionogi Recent Developments/Updates
- 2.5 Celon Laboratories
- 2.5.1 Celon Laboratories Details
- 2.5.2 Celon Laboratories Major Business
- 2.5.3 Celon Laboratories Ifosfamide for Injection Product and Services
- 2.5.4 Celon Laboratories Ifosfamide for Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.5.5 Celon Laboratories Recent Developments/Updates
- 2.6 Getwell Pharma
- 2.6.1 Getwell Pharma Details
- 2.6.2 Getwell Pharma Major Business
- 2.6.3 Getwell Pharma Ifosfamide for Injection Product and Services
- 2.6.4 Getwell Pharma Ifosfamide for Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.6.5 Getwell Pharma Recent Developments/Updates
- 2.7 Qilu Pharma (Hainan)
- 2.7.1 Qilu Pharma (Hainan) Details
- 2.7.2 Qilu Pharma (Hainan) Major Business
- 2.7.3 Qilu Pharma (Hainan) Ifosfamide for Injection Product and Services
- 2.7.4 Qilu Pharma (Hainan) Ifosfamide for Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.7.5 Qilu Pharma (Hainan) Recent Developments/Updates
- 2.8 Hengrui Pharma
- 2.8.1 Hengrui Pharma Details
- 2.8.2 Hengrui Pharma Major Business
- 2.8.3 Hengrui Pharma Ifosfamide for Injection Product and Services
- 2.8.4 Hengrui Pharma Ifosfamide for Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.8.5 Hengrui Pharma Recent Developments/Updates
- 2.9 Harbin Sanlian Pharma
- 2.9.1 Harbin Sanlian Pharma Details
- 2.9.2 Harbin Sanlian Pharma Major Business
- 2.9.3 Harbin Sanlian Pharma Ifosfamide for Injection Product and Services
- 2.9.4 Harbin Sanlian Pharma Ifosfamide for Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.9.5 Harbin Sanlian Pharma Recent Developments/Updates
- 2.10 Nanjing Pharmaceutical Factory
- 2.10.1 Nanjing Pharmaceutical Factory Details
- 2.10.2 Nanjing Pharmaceutical Factory Major Business
- 2.10.3 Nanjing Pharmaceutical Factory Ifosfamide for Injection Product and Services
- 2.10.4 Nanjing Pharmaceutical Factory Ifosfamide for Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.10.5 Nanjing Pharmaceutical Factory Recent Developments/Updates
- 2.11 Shanxi Pude Pharma
- 2.11.1 Shanxi Pude Pharma Details
- 2.11.2 Shanxi Pude Pharma Major Business
- 2.11.3 Shanxi Pude Pharma Ifosfamide for Injection Product and Services
- 2.11.4 Shanxi Pude Pharma Ifosfamide for Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.11.5 Shanxi Pude Pharma Recent Developments/Updates
3 Competitive Environment: Ifosfamide for Injection by Manufacturer
- 3.1 Global Ifosfamide for Injection Sales Quantity by Manufacturer (2021-2026)
- 3.2 Global Ifosfamide for Injection Revenue by Manufacturer (2021-2026)
- 3.3 Global Ifosfamide for Injection Average Price by Manufacturer (2021-2026)
- 3.4 Market Share Analysis (2025)
- 3.4.1 Producer Shipments of Ifosfamide for Injection by Manufacturer Revenue ($MM) and Market Share (%): 2025
- 3.4.2 Top 3 Ifosfamide for Injection Manufacturer Market Share in 2025
- 3.4.3 Top 6 Ifosfamide for Injection Manufacturer Market Share in 2025
- 3.5 Ifosfamide for Injection Market: Overall Company Footprint Analysis
- 3.5.1 Ifosfamide for Injection Market: Region Footprint
- 3.5.2 Ifosfamide for Injection Market: Company Product Type Footprint
- 3.5.3 Ifosfamide for Injection Market: Company Product Application Footprint
- 3.6 New Market Entrants and Barriers to Market Entry
- 3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
- 4.1 Global Ifosfamide for Injection Market Size by Region
- 4.1.1 Global Ifosfamide for Injection Sales Quantity by Region (2021-2032)
- 4.1.2 Global Ifosfamide for Injection Consumption Value by Region (2021-2032)
- 4.1.3 Global Ifosfamide for Injection Average Price by Region (2021-2032)
- 4.2 North America Ifosfamide for Injection Consumption Value (2021-2032)
- 4.3 Europe Ifosfamide for Injection Consumption Value (2021-2032)
- 4.4 Asia-Pacific Ifosfamide for Injection Consumption Value (2021-2032)
- 4.5 South America Ifosfamide for Injection Consumption Value (2021-2032)
- 4.6 Middle East & Africa Ifosfamide for Injection Consumption Value (2021-2032)
5 Market Segment by Type
- 5.1 Global Ifosfamide for Injection Sales Quantity by Type (2021-2032)
- 5.2 Global Ifosfamide for Injection Consumption Value by Type (2021-2032)
- 5.3 Global Ifosfamide for Injection Average Price by Type (2021-2032)
6 Market Segment by Application
- 6.1 Global Ifosfamide for Injection Sales Quantity by Application (2021-2032)
- 6.2 Global Ifosfamide for Injection Consumption Value by Application (2021-2032)
- 6.3 Global Ifosfamide for Injection Average Price by Application (2021-2032)
7 North America
- 7.1 North America Ifosfamide for Injection Sales Quantity by Type (2021-2032)
- 7.2 North America Ifosfamide for Injection Sales Quantity by Application (2021-2032)
- 7.3 North America Ifosfamide for Injection Market Size by Country
- 7.3.1 North America Ifosfamide for Injection Sales Quantity by Country (2021-2032)
- 7.3.2 North America Ifosfamide for Injection Consumption Value by Country (2021-2032)
- 7.3.3 United States Market Size and Forecast (2021-2032)
- 7.3.4 Canada Market Size and Forecast (2021-2032)
- 7.3.5 Mexico Market Size and Forecast (2021-2032)
8 Europe
- 8.1 Europe Ifosfamide for Injection Sales Quantity by Type (2021-2032)
- 8.2 Europe Ifosfamide for Injection Sales Quantity by Application (2021-2032)
- 8.3 Europe Ifosfamide for Injection Market Size by Country
- 8.3.1 Europe Ifosfamide for Injection Sales Quantity by Country (2021-2032)
- 8.3.2 Europe Ifosfamide for Injection Consumption Value by Country (2021-2032)
- 8.3.3 Germany Market Size and Forecast (2021-2032)
- 8.3.4 France Market Size and Forecast (2021-2032)
- 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
- 8.3.6 Russia Market Size and Forecast (2021-2032)
- 8.3.7 Italy Market Size and Forecast (2021-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Ifosfamide for Injection Sales Quantity by Type (2021-2032)
- 9.2 Asia-Pacific Ifosfamide for Injection Sales Quantity by Application (2021-2032)
- 9.3 Asia-Pacific Ifosfamide for Injection Market Size by Region
- 9.3.1 Asia-Pacific Ifosfamide for Injection Sales Quantity by Region (2021-2032)
- 9.3.2 Asia-Pacific Ifosfamide for Injection Consumption Value by Region (2021-2032)
- 9.3.3 China Market Size and Forecast (2021-2032)
- 9.3.4 Japan Market Size and Forecast (2021-2032)
- 9.3.5 South Korea Market Size and Forecast (2021-2032)
- 9.3.6 India Market Size and Forecast (2021-2032)
- 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
- 9.3.8 Australia Market Size and Forecast (2021-2032)
10 South America
- 10.1 South America Ifosfamide for Injection Sales Quantity by Type (2021-2032)
- 10.2 South America Ifosfamide for Injection Sales Quantity by Application (2021-2032)
- 10.3 South America Ifosfamide for Injection Market Size by Country
- 10.3.1 South America Ifosfamide for Injection Sales Quantity by Country (2021-2032)
- 10.3.2 South America Ifosfamide for Injection Consumption Value by Country (2021-2032)
- 10.3.3 Brazil Market Size and Forecast (2021-2032)
- 10.3.4 Argentina Market Size and Forecast (2021-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Ifosfamide for Injection Sales Quantity by Type (2021-2032)
- 11.2 Middle East & Africa Ifosfamide for Injection Sales Quantity by Application (2021-2032)
- 11.3 Middle East & Africa Ifosfamide for Injection Market Size by Country
- 11.3.1 Middle East & Africa Ifosfamide for Injection Sales Quantity by Country (2021-2032)
- 11.3.2 Middle East & Africa Ifosfamide for Injection Consumption Value by Country (2021-2032)
- 11.3.3 Turkey Market Size and Forecast (2021-2032)
- 11.3.4 Egypt Market Size and Forecast (2021-2032)
- 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
- 11.3.6 South Africa Market Size and Forecast (2021-2032)
12 Market Dynamics
- 12.1 Ifosfamide for Injection Market Drivers
- 12.2 Ifosfamide for Injection Market Restraints
- 12.3 Ifosfamide for Injection Trends Analysis
- 12.4 Porters Five Forces Analysis
- 12.4.1 Threat of New Entrants
- 12.4.2 Bargaining Power of Suppliers
- 12.4.3 Bargaining Power of Buyers
- 12.4.4 Threat of Substitutes
- 12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
- 13.1 Raw Material of Ifosfamide for Injection and Key Manufacturers
- 13.2 Manufacturing Costs Percentage of Ifosfamide for Injection
- 13.3 Ifosfamide for Injection Production Process
- 13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel
- 14.1 Sales Channel
- 14.1.1 Direct to End-User
- 14.1.2 Distributors
- 14.2 Ifosfamide for Injection Typical Distributors
- 14.3 Ifosfamide for Injection Typical Customers
15 Research Findings and Conclusion
16 Appendix
- 16.1 Methodology
- 16.2 Research Process and Data Source
According to our (Global Info Research) latest study, the global Ifosfamide for Injection market size was valued at US$ 216 million in 2025 and is forecast to a readjusted size of US$ 310 million by 2032 with a CAGR of 5.2% during review period.
Ifosfamide for Injection is a cytotoxic antineoplastic injectable formulation containing ifosfamide, a nitrogen-mustard alkylating agent supplied mainly as a sterile powder for injection or a ready-to-use injectable solution. After intravenous administration, its active metabolites alkylate DNA and inhibit tumor-cell replication and proliferation. It is used primarily in the treatment of testicular cancer, soft tissue sarcoma, bone sarcoma, lymphoma, ovarian cancer and selected other solid or hematologic malignancies, and is commonly administered with mesna to reduce the risk of urothelial toxicity such as hemorrhagic cystitis. Commercial presentations are concentrated in 0.5 g, 1.0 g, 2.0 g and 3.0 g strengths, with manufacturing requiring strict controls for sterility, impurities, dissolution or reconstitution performance, container integrity and segregation of cytotoxic production. In 2025, global Ifosfamide for Injection production reached approximately 10.8 million unit.
Underlying demand for Ifosfamide for Injection is supported by its long-established role in treatment regimens for sarcomas, relapsed or refractory germ-cell tumors and selected lymphomas. Although oncology is increasingly shifting toward targeted therapies, immunotherapies and cell-based treatments, ifosfamide retains clear clinical value in several established combination regimens, particularly in high-intensity cytotoxic therapy, salvage settings and perioperative chemotherapy. As cancer diagnosis and guideline-based treatment expand globally, the absolute requirement for established chemotherapy agents remains resilient.
A second growth driver is improving generic-drug accessibility together with the expansion of oncology treatment infrastructure in emerging markets. Growth in hospital infusion centers, day-care chemotherapy facilities and specialist cancer hospitals enables more patients to receive standardized combination chemotherapy, while local sterile-injectable capacity in China, India and other Asian markets is improving supply coverage and affordability. The availability of multiple dose strengths and both powder and ready-to-use liquid presentations also allows hospitals to select products that better fit treatment protocols, pharmacy workflows and compounding efficiency.
Supply security is becoming an increasingly important competitive factor. Ifosfamide is a high-control cytotoxic injectable that requires dedicated manufacturing areas, aseptic processing, occupational protection, cross-contamination controls and rigorous batch release. Any production interruption can quickly affect hospital availability, and recent injectable shortages in several markets have increased the importance placed on multi-source procurement, regional manufacturing and dependable inventory. Manufacturers with established sterile-oncology platforms, durable regulatory registrations and reliable international supply systems are therefore better positioned to secure recurring demand and market share.
Report Scope
This report is a detailed and comprehensive analysis for global Ifosfamide for Injection market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Ifosfamide for Injection market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Ifosfamide for Injection market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Ifosfamide for Injection market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Ifosfamide for Injection market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Ifosfamide for Injection
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Ifosfamide for Injection market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Baxter, Fresenius Kabi, Hikma, Shionogi, Celon Laboratories, Getwell Pharma, Qilu Pharma (Hainan), Hengrui Pharma, Harbin Sanlian Pharma, Nanjing Pharmaceutical Factory, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Ifosfamide for Injection market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market Segmentation
Market segment by Type
0.5 g
1.0 g
2.0 g
3.0 g
Other Strengths
Market segment by Dosage Form
Powder for Injection
Ready-to-Use Solution Injection
Other Dosage Forms
Market segment by Pack Configuration
Single-Vial Pack
Multi-Vial Pack
Other Pack Configurations
Market segment by Application
Testicular Cancer
Soft Tissue Sarcoma
Bone Sarcoma
Lymphoma
Ovarian Cancer
Other Malignancies
Major players covered
Baxter
Fresenius Kabi
Hikma
Shionogi
Celon Laboratories
Getwell Pharma
Qilu Pharma (Hainan)
Hengrui Pharma
Harbin Sanlian Pharma
Nanjing Pharmaceutical Factory
Shanxi Pude Pharma
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Chapter Outline
Chapter 1, to describe Ifosfamide for Injection product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Ifosfamide for Injection, with price, sales quantity, revenue, and global market share of Ifosfamide for Injection from 2021 to 2026.
Chapter 3, the Ifosfamide for Injection competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Ifosfamide for Injection breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Ifosfamide for Injection market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Ifosfamide for Injection.
Chapter 14 and 15, to describe Ifosfamide for Injection sales channel, distributors, customers, research findings and conclusion.